Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. (2023)

First Author: De Botton S
Attributed to:  Biology and Treatment of Human Myeloid Cancers funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2021014901

PubMed Identifier: 35714312

Publication URI: http://europepmc.org/abstract/MED/35714312

Type: Journal Article/Review

Volume: 141

Parent Publication: Blood

Issue: 2

ISSN: 0006-4971